Supplementary Data — Interferon-α for hantavirus: real-time meta-analysis of 1 study

@CovidAnalysis, May 2026, Version 1V1
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gui (RCT) 0% 1.00 [0.28-3.56] death 4/25 4/25 HFRS, Hantann Improvement, RR [CI] Treatment Control Gui (RCT) 67% 0.33 [0.04-2.99] progression 1/25 3/25 HFRS, Hantann Gui (RCT) 43% 0.57 [0.19-1.71] progression 4/25 7/25 HFRS, Hantann Gui (RCT) -32% 1.32 [1.24-1.42] no recov. 25 (n) 25 (n) HFRS, Hantann Interferon-α hantavirus outcomes c19early.org May 2026 Favors interferon-α Favors control
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.